Effect of hypoalbuminemia on the pharmacokinetics of esomeprazole in ICU critical ill patients

Status

Active, not recruiting

Phases

Phase 4

Study type

Observational

Source

ChiCTR

Registry ID

ChiCTR1800018516

Enrollment

Unknown

Registered

2018-09-21

Start date

2017-01-01

Completion date

Unknown

Last updated

2018-09-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

hypoalbuminemia

Interventions

Case series:esomeprazole

Eligibility

Sex/Gender

All

Age

18 Years to 90 Years

Inclusion criteria

Inclusion criteria: 1. get informed consent; 2. acute physiology and chronic health assessment (APACHE-II) score 11~30; 3. aged 18 to 90 years old, sex is not limited; 4. woman or may be pregnant should be confirmed that there is no pregnancy or non lactation.

Exclusion criteria

Exclusion criteria: 1. lactating or pregnant women; 2. participated in other clinical trials within 30 days before the screening period. 3. patients with severe liver dysfunction (Child-Pugh grade C); 4. Patients with acute upper gastrointestinal bleeding, peptic ulcer bleeding, peptic ulcer/gastric ulcer, gastroesophageal reflux disease, Zollinger-Ellison syndrome or other purposes requiring Esomeprazole over 40 mg for one day; 5. cannot or unwilling to provide informed consent or poor compliance.

Design outcomes

Primary

Measure	Time frame
Plasma albumin;Blood concentration of esomeprazole;CYP2C19 genotype;	—

Countries

China

Contacts

Public ContactChuxiao Shao

Lishui Central Hospital

scx1212@163.com+86 0578-2285102

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026